Prof Maree Smith

Australian pain drug innovation company Spinifex Pharmaceuticals sold to Novartis for US$200m plus milestone payments

GBS Ventures reports Novartis has agreed to acquire chronic-pain drug developer Spinifex Pharmaceuticals for US$200 million upfront plus milestones, recalling the company's 2005, 2008 and 2014 venture rounds and its Australian investors.

Also GBS Ventures·novartis.com·clinicalleader.com·Startup Daily·Startup Daily·anthillonline.com·@AuManufacturing·materresearch.org.au·Business News Australia

Spinifex Pharmaceuticals to be Acquired by Novartis - PR Newswire

Chronic-pain drug developer Spinifex Pharmaceuticals has agreed to be bought by Novartis for US$200 million upfront plus undisclosed milestones, centred on its lead candidate EMA401.

Also news-medical.net·bionity.com

EP Vantage Interview – Spinifex seeking to heal the pain with new approach

Profile of Australian biotech Spinifex Pharmaceuticals and its neuropathic pain drug EMA401, covering phase II trials, the science behind its AT2 approach, and its venture backers as it weighs a future series C.

$1.67 Million Grant To Develop Pain Drug

Spinifex Pharmaceuticals won a $1.67 million federal Commercial Ready grant to advance its neuropathic pain drug, after a $3.25 million syndicate raise the previous July; it was spun out of the University of Queensland.

SPINIFEX SECURES $3.25 M INVESTMENT TO DEVELOP PAIN THERAPY

University of Queensland spinout Spinifex Pharmaceuticals landed $3.25 million from Symbiosis, GBS Venture Partners and Uniseed to advance its neuropathic pain therapy toward toxicology testing.

Also GBS Ventures·GBS Ventures·clinicalleader.com·bionity.com